(EVMN) Evommune - Overview
Sector: Healthcare | Industry: Biotechnology | Exchange: NYSE (USA) | Market Cap: 788m USD | Total Return: 13.1% in 12m
Avg Turnover: 8.24M
Warnings
Interest Coverage Ratio -26853.3 is critical
Altman Z'' -15.00 < 1.0 - financial distress zone
Choppy
Tailwinds
No distinct edge detected
Evommune, Inc. (EVMN) is a Palo Alto-based, clinical-stage biotechnology firm focused on chronic inflammatory diseases. The company’s primary pipeline includes EVO756 and EVO301, which are currently being evaluated for the treatment of chronic spontaneous urticaria, atopic dermatitis, and ulcerative colitis.
The biotechnology sector typically operates on a high-risk, high-reward model characterized by significant research and development expenses prior to achieving commercial revenue. Success for clinical-stage companies often depends on the progression of drug candidates through rigorous FDA-mandated trial phases to demonstrate safety and efficacy.
Investors should consult ValueRay to analyze the underlying financial health and valuation metrics of this ticker. Given the volatility inherent in the biotech industry, monitoring clinical data readouts is essential for assessing long-term growth potential.
- EVO756 clinical trial data readouts drive near-term stock price volatility
- Regulatory approval progress for EVO301 determines long-term commercial viability
- R&D expenditure levels impact cash runway and future financing needs
- Competitive landscape in chronic inflammatory disease market affects projected market share
- Success of initial programs dictates expansion into broader autoimmune indications
| Net Income: -76.0m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.25 > 0.02 and ΔFCF/TA 119.9 > 1.0 |
| NWC/Revenue: 1.58k% < 20% (prev 1.08k%; Δ 502.6% < -1%) |
| CFO/TA -0.25 > 3% & CFO -80.0m > Net Income -76.0m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 20.36 > 1.5 & < 3 |
| Outstanding Shares: last quarter (33.7m) vs 12m ago 11.94% < -2% |
| Gross Margin: 89.53% > 18% (prev 0.77%; Δ 8.88k% > 0.5%) |
| Asset Turnover: 6.87% > 50% (prev 5.36%; Δ 1.51% > 0%) |
| Interest Coverage Ratio: -26.9k > 6 (EBITDA TTM -79.2m / Interest Expense TTM 3.00k) |
| A: 0.64 (Total Current Assets 215.9m - Total Current Liabilities 10.6m) / Total Assets 322.5m |
| B: -0.75 (Retained Earnings -242.8m / Total Assets 322.5m) |
| C: -0.43 (EBIT TTM -80.6m / Avg Total Assets 189.2m) |
| D: -13.56 (Book Value of Equity -242.8m / Total Liabilities 17.9m) |
| Altman-Z'' = -15.38 = D |
As of May 24, 2026, the stock is trading at USD 23.55 with a total of 603,926 shares traded.
Over the past week, the price has changed by -0.22%,
over one month by -15.67%,
over three months by -17.11% and
over the past year by +13.05%.
Evommune has no consensus analysts rating.
P/B = 2.5888
Revenue TTM = 13.0m USD
EBIT TTM = -80.6m USD
EBITDA TTM = -79.2m USD
Long Term Debt = 7.30m USD (estimated: total debt 9.11m - short term 1.82m)
Short Term Debt = 1.82m USD (from shortTermDebt, last quarter)
Debt = 10.8m USD (from shortLongTermDebtTotal, last quarter) + Leases 1.71m
Net Debt = -200.6m USD (calculated: Debt 10.8m - CCE 211.5m)
Enterprise Value = 587.8m USD (788.4m + Debt 10.8m - CCE 211.5m)
Interest Coverage Ratio = -26.9k (Ebit TTM -80.6m / Interest Expense TTM 3.00k)
EV/FCF = -7.31x (Enterprise Value 587.8m / FCF TTM -80.4m)
FCF Yield = -13.67% (FCF TTM -80.4m / Enterprise Value 587.8m)
FCF Margin = -618.2% (FCF TTM -80.4m / Revenue TTM 13.0m)
Net Margin = -584.5% (Net Income TTM -76.0m / Revenue TTM 13.0m)
Gross Margin = 89.53% ((Revenue TTM 13.0m - Cost of Revenue TTM 1.36m) / Revenue TTM)
Gross Margin QoQ = none% (prev none%)
Tobins Q-Ratio = 1.82 (Enterprise Value 587.8m / Total Assets 322.5m)
Interest Expense / Debt = 0.03% (Interest Expense 3.00k / Debt 10.8m)
Taxrate = 21.0% (US default 21%)
NOPAT = -63.6m (EBIT -80.6m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 20.36 (Total Current Assets 215.9m / Total Current Liabilities 10.6m)
Debt / Equity = 0.04 (Debt 10.8m / totalStockholderEquity, last quarter 304.6m)
Debt / EBITDA = 2.53 (negative EBITDA) (Net Debt -200.6m / EBITDA -79.2m)
Debt / FCF = 2.50 (negative FCF - burning cash) (Net Debt -200.6m / FCF TTM -80.4m)
Total Stockholder Equity = 38.9m (last 4 quarters mean from totalStockholderEquity)
RoA = -40.15% (Net Income -76.0m / Total Assets 322.5m)
RoE = -26.97% (Net Income TTM -76.0m / Total Stockholder Equity 281.7m)
RoCE = -27.88% (EBIT -80.6m / Capital Employed (Equity 281.7m + L.T.Debt 7.30m))
RoIC = -20.82% (negative operating profit) (NOPAT -63.6m / Invested Capital 305.7m)
WACC = 14.98% (E(788.4m)/V(799.3m) * Re(15.19%) + D(10.8m)/V(799.3m) * Rd(0.03%) * (1-Tc(0.21)))
Discount Rate = 15.19% (= CAPM, Blume Beta Adj.) -> capped to 13.17%
Shares (quarterly) Correlation: 70.0 | Cagr: 5.80%
[DCF] Fair Price = unknown (Cash Flow -80.4m)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: N/A | # QB: 0
Revenue Correlation: 98.57 | Revenue CAGR: 61.25% | SUE: N/A | # QB: 0
EPS current Quarter (2026-06-30): EPS=-0.68 | Chg30d=+1.61% | Revisions=+0% | Analysts=8
EPS next Quarter (2026-09-30): EPS=-0.69 | Chg30d=-5.07% | Revisions=+0% | Analysts=8
EPS current Year (2026-12-31): EPS=-2.78 | Chg30d=+13.54% | Revisions=+33% | GrowthEPS=+75.2% | GrowthRev=-48.8%
EPS next Year (2027-12-31): EPS=-3.33 | Chg30d=+1.06% | Revisions=+33% | GrowthEPS=-19.9% | GrowthRev=-88.4%
[Analyst] Revisions Ratio: +33%